Patient-Centered Economic Burden of Diabetic Macular Edema: Retrospective Cohort Study.

ABSTRACT:

Background

Diabetic macular edema (DME), a leading cause of blindness, requires treatment with costly drugs, such as anti-vascular endothelial growth factor (VEGF) agents. The prolonged use of these effective but expensive drugs results in an incremental economic burden for patients with DME compared with those with diabetes mellitus (DM) without DME. However, there are no studies on the long-term patient-centered economic burden of DME after reimbursement for anti-VEGFs.

Objective

This retrospective cohort study aims to estimate the 3-year patient-centered economic burden of DME compared with DM without DME, using the Common Data Model.

Methods

We used medical data from 1,903,603 patients (2003-2020), transformed and validated using the Observational Medical Outcomes

SUBMITTER: Choi K 

PROVIDER: S-EPMC11496919 | biostudies-literature | 2024 Oct

REPOSITORIES: biostudies-literature